Fosamax Exposure and Osteonecrosis of the Jaw: A Review of Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Pharmacovigilance

The legacy of general health and science information dissemination has long served as a cornerstone for public understanding, providing foundational knowledge that empowers individuals to engage with medical topics from a place of informed awareness. This heritage, rooted in accessible communication from institutions like community medical centers, has traditionally focused on broad wellness principles, preventive care, and the navigation of healthcare services. Such contexts establish a baseline for how health risks are conceptualized and discussed within the public sphere. Transitioning from this general framework, a more targeted concern emerges when considering specific pharmaceutical exposures and their potential long-term implications. The shift from broad health education to a focused patient exposure scenario requires careful attention to how risk is communicated. In particular, the discussion around bisphosphonate therapy, such as Fosamax, and its association with osteonecrosis of the jaw represents a pivot from general health maintenance to a specialized area of pharmacovigilance. This transition underscores the need to move from abstract health literacy to concrete exposure contexts, where the mechanisms of risk and the weight of evidence become central to clinical and occupational safety discussions.

Bridging General Wellness to Specific Exposure Risks

Building on the foundation of general health education, this section explicitly bridges the gap to the specific risks associated with Fosamax exposure. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. This narrative examines the clinical presentation, pharmacological mechanisms, and causation-related considerations linking Fosamax exposure to ONJ, based on available evidence.

Clinical Presentation and Risk Factors for ONJ

Osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Clinical presentation typically involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or loosening of teeth. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease.

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which is the intended therapeutic effect for osteoporosis. However, this suppression of bone turnover may impair the jawbone's ability to repair microdamage and respond to local stressors such as dental procedures or infection. Multiscale characterization of jawbone in animal models treated with bisphosphonates provides information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the structural and mechanical properties of jawbone, potentially predisposing it to necrosis under conditions of stress or infection.

Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and notes known risk factors such as invasive dental procedures, cancer diagnosis, and concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). It also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting the drug can vary from one day to several months, and discontinuation is recommended if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, though a subset may have recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline can vary, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Other factors, such as the presence of known risk factors like dental procedures or cancer, must be considered in assessing individual causation. The label notes that ONJ can occur spontaneously, complicating the attribution to drug exposure alone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative debridement, infection control, and avoidance of further invasive dental procedures. The evidence supports a plausible link between Fosamax and ONJ, particularly in the presence of risk factors, but individual cases require careful evaluation of exposure history, clinical presentation, and alternative causes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used for osteoporosis. Its use has been associated with osteonecrosis of the jaw (ONJ), a condition of exposed non-healing bone in the jaw. The risk is higher with invasive dental procedures, longer duration of use, and other risk factors like cancer or corticosteroid therapy. The prescribing information includes warnings about ONJ.

What are the mechanisms by which Fosamax may cause ONJ?

Fosamax inhibits osteoclast-mediated bone resorption, which suppresses bone turnover. This may impair the jawbone's ability to repair microdamage and respond to stressors like dental procedures or infection. Animal studies show altered structural and mechanical properties of jawbone after alendronate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077).

How is causation between Fosamax and ONJ established?

Causation requires a temporal relationship between Fosamax exposure and ONJ onset, which can range from one day to several months. Risk increases with longer use. Other factors like dental procedures or cancer must be considered. ONJ can also occur spontaneously, complicating attribution. Management includes drug discontinuation and conservative treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.